{
  "_id": "455e0f7f0964894c89db3e2aff442832e7f9ab2ae038b3114950f2c67d831e81",
  "feed": "market-watch",
  "title": "Biotech rout in 2021 has led to some massive hedge-fund losses",
  "text": "<p>The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as&#xa0;the IPO market booms.</p><p>Perceptive Advisors, a prominent biotech hedge fund that manages about $9 billion, lost about 30% this year through November in its main fund, investors say. A hedge fund managed by OrbiMed Partners, which invests more than $18 billion in healthcare in public and private markets, has lost more than 40% this year through November, people familiar with the fund say. Both funds had scored big gains over the past two years.</p><p>Meanwhile, a hedge fund run by San Francisco-based Logos Capital, which manages about $1.4 billion, is down more than 25% for the period, other people say. Cormorant Asset Management lost 10% in November alone, adding to double-digit losses earlier in the year.</p><p>“It's been a very challenging year,” said Bihua Chen, founder of Cormorant, which focuses on smaller biotech companies.</p><p>An expanded version of this report appears on WSJ.com.</p><p>Also popular on WSJ.com:</p><p>Apple's iPhone successor comes into focus.</p><p>China seeks first military base on Africa's Atlantic coast, U.S. intelligence finds.</p>",
  "published": "2021-12-05T19:30:00.000Z",
  "tags": [
    {
      "id": "US0378331005",
      "name": "Apple Inc.",
      "offsets": [
        {
          "start": 1044,
          "end": 1049
        }
      ],
      "nexusId": "10022657"
    }
  ]
}